Nadia Drider is leading business development efforts across France, Switzerland and Southern Europe. She is your point of contact for BioAgilytix bioanalytical offering including tailored services for pharmacokinetics (PK), immunogenicity, biomarkers, cell-based assays. This includes cell- & gene therapy, monoclonal antibodies, complex bi-/tri-specific and other fusion molecule/ protein formats and Antibody Drug Conjugates.

Nadia has a background in human physiopathology with a PhD in Immunology from University Paul Sabatier (Toulouse) and over 16 years of experience within bioanalytical contract research.

Robert Nelson, PhD, is a member of the BioAgilytix Scientific Office, focusing on our EU team to address science, technology, and regulatory challenges. Spending over fifteen years working in regulated (GLP/GCP) laboratory environments, Dr. Nelson supports preclinical and clinical drug development programs, with broad experience in bioanalytical support for assessment of pharmacokinetics, immunogenicity, and biomarkers. Prior to BioAgilytix Dr. Nelson held senior scientific leadership roles with Covance/Labcorp Drug Development and Swiss biotech company Novimmune. Dr. Nelson holds a PhD in Molecular Physiology from the University of Edinburgh.

Dany Spaggiari is a Senior Scientist in Bioanalysis at Debiopharm International, where he leads bioanalytical strategies supporting both preclinical and clinical drug development, with a particular focus on complex modalities such as antibody–drug conjugates and radioligand therapies. He has contributed to multiple first-in-human programs and to the complex setup of Phase III blinded studies, providing strategic leadership in method development, sample management, and regulatory submissions, with a strong emphasis on robust assay design, risk mitigation, and innovative solutions to analytical challenges.

He obtained his PhD in Pharmaceutical Sciences from the University of Geneva and subsequently completed a research fellowship in the Clinical Pharmacology Laboratory at Lausanne University Hospital, before joining Debiopharm in 2018.

Laura von Berg is a Principal Investigator at BioAgilytix Europe GmbH, Hamburg, where she leads the development, validation, and application of bioanalytical assays for pharmacokinetics, pharmacodynamics, and immunogenicity in support of clinical and preclinical studies. Laura obtained her bachelor's degree in Biological Sciences from the University of Konstanz, followed by a master's in molecular medicine from Charité – University Medicine Berlin. She earned her PhD in Biology and Biochemistry at Freie Universität Berlin for work conducted at the Robert Koch Institute. Before joining BioAgilytix in 2021, she was a Project Manager at the Joachim Herz Foundation in Hamburg.